Online and automated E. coli monitoring for 100% safe drinking water

Projektinformationen

ColiSense Online

ID Finanzhilfevereinbarung: 809065

DOI

10.3030/809065

Projekt abgeschlossen

EK-Unterschriftsdatum 10 Februar 2018

Startdatum 1 März 2018

Enddatum 30 Juni 2018

Finanziert unter

• SOCIETAL CHALLENGES - Climate action, Environment, Resource Efficiency and Raw Materials

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

BNOVATE TECHNOLOGIES SA
Switzerland

Periodic Reporting for period 1 - ColiSense Online (Online and automated E. coli monitoring for 100% safe drinking water)

Berichtszeitraum: 2018-03-01 bis 2018-06-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

The presence of E. coli in drinking water is a clear indication of fecal contamination and makes the water unsafe to drink. More than 300,000 cases of waterborne disease due to microbiological contamination are reported yearly in Europe according to the WHO. bNovate Technologies AG aims to bring to industrial production stage ColiSense, a quick (60 min), inexpensive (€1 per analysis) and accurate analyzer capable of detecting and quantifying E. coli cells in drinking water below the regulation threshold limits (1 cell per 100 ml). The technology behind ColiSense is flow cytometry, technology that bNovate has brought for the first time to industrial scale in a fully-automated manner.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

During our 4-month Feasibility Study several activities have been carried out. First, the technical specifications of ColiSense’s subsystems have been defined. Following, a risk analysis has been conducted to ensure that no issues have been left aside and that future development will be with a low and controlled risk. Our team prepared a complete Execution Plan for the development and exploitation of ColiSense; we also identified the most beneficial partners to support us in the execution and exploitation of the Phase 2 project. Regarding commercial feasibility assessment, we have focused on the potential new markets which has allowed us to prepare our marketing and pricing strategy. Furthermore, a complete Freedom-to-Operate was performed and confirmed 1) the novelty of the ColiSense and 2) the absence of existing thread for its commercialization. Finally, financial projections for the 2021-2026 period have been calculated, and we expect a highly positive turnover.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

We have designed a commercialisation strategy covering a wide range of end-user industries. Our targeted sectors are waterworks and bottled water industries which, together, cover almost the entire drinking water production market. ColiSense meets the real needs of our customers such as: 1) being compliant with EU legislation, 2) fast E. coli detection (60 min), 3) low operation and maintenance cost; 4) easy to use (no qualified personnel is needed to operate it), and 5) low investment cost (4 years amortization). The Return on Investment (ROI) of ColiSense is 4.68 taken into account the total investment and the accumulated profit. Pay-back of the project will be achieved at the second year of commercialization.

Project Logo

Company logo